A Real-World Cost-Effectiveness Analysis of Rivaroxaban versus Vitamin K Antagonists for the Treatment of Symptomatic Venous Thromboembolism: Lessons from the REMOTEV Registry

Background and objectives: Venous thromboembolism (VTE) represents a health and economic burden with consequent healthcare resource utilization. Direct oral anticoagulants (DOACs) have emerged as the mainstay option for VTE treatment but few data exist on their cost-effectiveness as compared to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kepka, Sabrina, Cordeanu, Elena-Mihaela, Zarca, Kevin, Frantz, Anne-Sophie, Ohlmann, Patrick, Andres, Emmanuel, Bilbault, Pascal, Durand-Zaleski, Isabelle, Stephan, Dominique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867052/
https://www.ncbi.nlm.nih.gov/pubmed/36676804
http://dx.doi.org/10.3390/medicina59010181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867052/
https://www.ncbi.nlm.nih.gov/pubmed/36676804
http://dx.doi.org/10.3390/medicina59010181

Ejemplares similares